Literature DB >> 8416409

Diagnosis and treatment of Clostridium difficile colitis.

R Fekety1, A B Shah.   

Abstract

Pseudomembranous colitis associated with antibiotic therapy is almost always due to an overgrowth of Clostridium difficile. If untreated, pseudomembranous colitis can lead to severe diarrhea, hypovolemic shock, toxic dilatation of the colon, cecal perforation, hemorrhage, and death. However, C difficile-associated colitis can mimic the more common "benign" antibiotic-associated diarrhea that is not caused by C difficile. An algorithm for diagnosis management of hospitalized patients with antibiotic diarrhea and C difficile colitis is presented in this review. Diagnosis depends on sigmoidoscopy and/or stool tests for C difficile toxins in all patients with antibiotic-associated diarrhea. If the results of these tests are positive, either metronidazole or vancomycin is recommended for treatment of mild illness, and vancomycin is recommended for treatment of severe illness. Oral therapy is always preferred because it is more reliable. In patients with recurrent or relapsing colitis, treatment with either metronidazole or vancomycin is effective for that episode, but novel approaches, such as the oral or rectal introduction of competing nonpathogenic organisms, may prove to be more successful in prevention of relapses.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8416409

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  48 in total

1.  Activities of synthetic hybrid peptides against anaerobic bacteria: aspects of methodology and stability.

Authors:  H Oh; M Hedberg; D Wade; C Edlund
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

Review 2.  Drug-induced Clostridium difficile-associated disease.

Authors:  M L Job; N F Jacobs
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

3.  Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.

Authors:  Kim L Credito; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

4.  Identification of a genetic locus responsible for antimicrobial peptide resistance in Clostridium difficile.

Authors:  Shonna M McBride; Abraham L Sonenshein
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

5.  Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses.

Authors:  Y K Shue; P S Sears; S Shangle; R B Walsh; C Lee; S L Gorbach; F Okumu; R A Preston
Journal:  Antimicrob Agents Chemother       Date:  2008-02-11       Impact factor: 5.191

6.  Does PPI therapy predispose to Clostridium difficile infection?

Authors:  Chaitanya Pant; Phillip Madonia; Anil Minocha
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09       Impact factor: 46.802

Review 7.  Pseudomembranous colitis.

Authors:  Priya D Farooq; Nathalie H Urrunaga; Derek M Tang; Erik C von Rosenvinge
Journal:  Dis Mon       Date:  2015-03-11       Impact factor: 3.800

8.  Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection.

Authors:  T Louie; M Miller; C Donskey; K Mullane; E J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

9.  Six rapid tests for direct detection of Clostridium difficile and its toxins in fecal samples compared with the fibroblast cytotoxicity assay.

Authors:  David K Turgeon; Thomas J Novicki; John Quick; LaDonna Carlson; Pat Miller; Bruce Ulness; Anne Cent; Rhoda Ashley; Ann Larson; Marie Coyle; Ajit P Limaye; Brad T Cookson; Thomas R Fritsche
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

10.  Clostridium difficile in urology.

Authors:  M Hossain; T J Crook; S R Keoghane
Journal:  Ann R Coll Surg Engl       Date:  2008-01       Impact factor: 1.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.